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Abstract. The human lymphocyte homing receptor
LAM-1, like its murine counterpart MEL-14, functions
as a mammalian lectin, and mediates the binding of
leukocytes to specialized high endothelial cells in lym-
phoid organs (HEV). LAM-1 is a member of a new
family of cell adhesion molecules, termed selectins or
LEC-CAMs, which also includes ELAM-1 and PAD-
GEM (GMP-140/CD62). To localize the regions of
LAM-1 that are involved in cell adhesion, we developed
chimeric selectins, in which various domains of PAD-
GEM were substituted into LAM-1, and used these chim-
eric proteins to define the domain requirements for car-
bohydrate binding, and to localize the regions recognized
by several mAb which inhibit the adhesion of lympho-
cytes to lymph node HEV. The binding of PPME or
fucoidin, soluble complex carbohydrates that specifically
define the lectin activity of LAM-1 and MEL-14, re-
quired only the lectin domain of LAM-1. The LAMM,
LAMI-3, and LAMI-6 mAb each strongly inhibit the
T
HE interaction of circulating leukocytes with vascular
endothelium underlies a number of phenomena im-
portant to host defense. The recirculation oflympho-
cytes throughout the secondary lymphoid organs, a process
which is necessary to ensure that the full complementof an-
tigen receptors is available throughout the organism, and the
recruitment of leukocytes to sites of inflammation, are each
regulated principally at the level of binding of leukocytes to
specially modified regions of the vessel wall. A number of
leukocyte and endothelial cell surface molecules that partici-
pate in this process have been identified and characterized
in both mouse and man. Among the best characterized ofthe
leukocyte receptors is the murine lymph node homing recep-
tor MEL-14 (10, 24, 31), and its human counterpart, the leu-
kocyte adhesion molecule-1 (LAM-1) (21, 42, 43), which
mediate the binding of lymphocytes to the specialized high
walled endothelium in the postcapillary venules present in
most secondary lymphoid organs (high endothelial venules
or HEV) .' (LAM-1 is recognized by the Leu-8, TQI, and
1. Abbreviations used in this paper: HEV, high endothelial venules; PCR,
polymerase chain reaction; SCR, short concensus repeat.
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binding of lymphocytes to HEV in the in vitro frozen
section assay, and defined three independent epitopes
on LAM-1. Blocking of PPME or fucoidin binding by
LAMI-3 indicated that this site is identical, or in close
proximity, to the carbohydrate binding site, and anal-
ysis of the binding of LAMI-3 to chimeric selectins
showed that the epitope detected by LAMI-3 is located
within the lectin domain. Although the LAMI-6 epitope
is also located in the lectin domain, LAMI-6 did not
affect the binding of PPME or fucoidin. The LAMl-1
epitope was located in, or required, the EGF domain,
and, importantly, binding of LAMl-1 significantly en-
hanced the binding of both PPME and fucoidin. These
results suggest that adhesion mediated by LAM-1 may
involve cooperativity between functionally and spatially
distinct sites, and support previous data suggesting a
role for the EGF domain of LAM-1 in lymphocyte ad-
hesion to HEV
DREG series mAb, in addition to the ones described in this
report, and has also been referred to as LEC-CAM-1 and
LECAM-1 .) These molecules are also expressed on other
classes of leukocytes, including neutrophils and monocytes
(13, 19, 43), and recent evidence suggests a role for LAM-1/
MEL-14 in the recruitment ofleukocytes to inflammatory le-
sions (18, 25, 47) . In man, LAM-1 is also expressed on the
majority ofcirculating hematopoietic stem cells (13), raising
the possibility that this molecule is also involved in stem
cell traffic.
A diverse array of functional evidence has clearly demon-
strated that these homing receptors function as mammalian
lectins. Thus, binding of lymphocytes to LN HEV, but not
Peyer's patchHEV, is specifically inhibited by certain simple
sugars, including mannose-6-phosphate (M6P) andthe struc-
turally related fructose-l-phosphate, by PPME, a M6P-rich
mannan core from the yeast Hansenula holsdi, and by fu-
coidin, a fucose-rich polysaccharide (38-40, 48, 49). PPME
and fucoidin bind specifically to LAM-1 and MEL-14, and
this binding is inhibited by some antibodies that selectively
bind to these HEV receptors and thereby inhibit the binding
oflymphocytes to LN HEV (21, 34,48). Inaddition, thebind-
351ing of PPME or fucoidin to LAM-1 or MEL-14 and of lym-
phocytes to LN HEV exhibits an identical absolute require-
ment for Caz+ (37, 40) . The lectin activity of MEL-14 has
recently been directly confirmed using purified MEL-14 pro-
tein (15). These data have firmly established an essential role
for specific recognition ofcarbohydrate in adhesion mediated
by this class of cell adhesion molecules.
Molecular cloning of MEL-14 (24, 31) and LAM-1 (3, 6,
30, 42) has recently revealed that these molecules are mem-
bers of a larger family of cell adhesion molecules. Termed
LEC-CAMs (36) or selectins (11, 35), this family also in-
cludes ELAM-1, which is expressed on cytokine treated en-
dothelium and mediatesthe bindingofleukocytes, principally
neutrophils, to these cells (1, 2) ; and PADGEM (GMF140,
CD62), which is expressed on activated platelets and endo-
thelium, and mediates the binding of these cells to mono-
cytes and neutrophils (11, 16, 22). Selectins are characterized
by a novel arrangement of distinct protein motifs, the most
prominent of which is an amino-terminal C-type lectin do-
main, consistent with the functional evidence described
above. This is followed by a domain homologousto EGF, a
variablenumber (twoinLAM-1 and MEL44, six in ELAM-1,
and nine in PADGEM [36]) of tandem repeats homologous
to complementregulatory proteins, a transmembrane region,
and a cytoplasmic tail. Although the presence of a C-type
lectin domain in these molecules is an elegant confirmation
of the functional data described above, the function of these
various domains in the adhesive or other biological proper-
ties of the selectins remains incompletely understood.
A requisite role for activation of adhesion molecules in
efficient cell adhesion has been suggested by studies of sev-
eral members of the integrin family (9, 29, 35). Consistent
with this hypothesis, we have recently shown that activation
ofleukocytes induces a rapid and transient increase in adhe-
sion mediated by LAM-1, and that this enhancement involves
an increase in affinity of LAM-1 for carbohydrate (34). In
this study, we have used chimeric selectins, in which various
regions of PADGEM have been substituted for those of
LAM-1, to define the domains responsible for carbohydrate
binding by LAM-1, and to identify other regions of the
LAM-I molecule involved in cell adhesion and receptor reg-
ulation. The results suggest that LAM-1-mediated adhesion
may involve the coordinated action of multiple sites withi
the molecule, not all ofwhich are directly involved in carbo-
hydrate recognition.
Materials andMethods
ProductionofmAbto LAM-1
The production and detailed characterization of the anti-LAM-1 mAb used
in this reportwill bedescribed elsewhere (34a). Briefly, the 300.19 munne
pre-B cell linewas transfected with LAM-1 eDNA (42) and usedto immunize
mice, as described (43). Antibodies that stained the LAM-transfected but
not the parent cell line were subeloned and analyzed further. This report
uses three such mAbs, termed LAMI-1, LAMi-3, and LAMi-6.
Effect ofAnti-LAM-1 mAbon BindingofPPME
orFucoidin
Peripheral blood lymphocytes were isolated by Ficoll-hypaque gradients.
The cells were incubated on ice for 15 min in PBS containing 1% FCS and
excess amounts ofunlabeled antibody inthe formofdiluted ascites, andei-
ther PPME-FITC or facoidin-FITC, prepared as described (12), was
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addedat previously determined optimal concentrations. After a further in-
cubation of 15 min, the cells were washed, and analyzed on an EPICS
Profile.
Construction ofChimeric Selectins
Four new restriction endonuclease recognition sites were introduced sep-
arately into the pLAM-1 eDNA (42) by polymerase chain reaction (PCR)-
based site-directed mutagenesis as follows. Oligonucleotides surrounding
and including each new restriction sequence were synthesized in both the
sense and antisense directions. PCR was carried out using the new restric-
tion site sense oligonucleotide + an antisense oligonucleotide anchor lo-
cated in the plasmid near the 3' end of the eDNA. In a separate reaction,
the new restriction site antisense oligonucleotide plus a sense oligonucleo-
tide anchor from the plasmid 5' end were used to amplify the 5' end of the
LAM-1 eDNA. The individual PCRproducts from these two reactions were
gel purified, subeloned into the pSP65 vector (Promega Biotec, Madison,
WI), digested with the appropriate restriction enzymes, and ligated together.
The nucleotide changes were as follows: (a) GA361ATCC to GGATCC in
thelectindomain, creatingaBamHl site, corresponding to aminoacid num-
ber 53 inthe mature protein (42); (b) A583TGCAG to CTOCAG in the EGF
domain, creating a Psd site, corresponding to amino acid number 127; (c)
GAGGssICss2C to GAGCTC in the first SCR domain, creating a Sacl site,
corresponding to amino acid number 164; and (d) GTCAAA1023 to
GTCAAC in the secondSCRdomain, creating aHincll site, corresponding
to amino acid number 279 (Fig. 1). The fidelity of the site-directed muta-
genesis was confirmed by restriction mapping and sequence analysis of the
cDNAs. Each of these sites is naturally present in the PADGEM eDNA
(23). Chimeric selectins were created by exchanging the indicated regions
ofLAM-1 and PADGEM (Fig. 1). CreationoftheSacl siteinvolvedasubsti-
tution of leu for ala; creation of the HincIl site involved a substitution of
thr for asn. These amino acid changes did not affectthe level ofexpression
of the mutants as detected by transient transfection in COS cells (data not
shown).
Domain MappingofBindingSitesforPPME,
Fucoidin, andmAbtoLAM-1
The chimeric selectin cDNAs were subeloned into the APTm8 expression
vector andtransient transfection of COS cells was performed by the DEAE
dextranmethod. 1 d after transfection, COS cells werereplatedontoplastic
microscope coverslips. On day 2 after transfection, COS cells were incu-
bated at room temperature for 30 min in humidified chambers with mAb
to LAM-1 inthe form ofascites fluid diluted in PBS/1% FCS, gently washed
with PBS/1% FCS, and incubated similarly with fluoresceinated goat anti-
body to mouse Ig (Tago Inc., Burlingame, CA). For carbohydrate binding
studies, a similar procedure was followed, except that PPME-FiTC or fu-
coidin-FITC were used. The cells were then mounted in Fluoromount-G
(Fisher-Biotech, Pittsburgh, PA), and examined by fluorescence micros-
copy. Staining wasconsidered positive only ifclear membrane staining out-
liningthecell was seen. Scoringwasas follows: 0, nostaining; +, 2-10%+;
++, 10-25% +; +++, 25-50% +;++++, >50% + . Negative controls in-
cluded transfection of COS cells with vector alone, vector with irrelevant
eDNA (e.g., CD19) (41), and staining with ascites of irrelevant specificity,
and these samples alwaysexhibitedt1% staining. ExpressionofLIP, which
isnotdetected byanyoffourteen anti-LAM-1 mAbexamined, was confirmed
by staining with the AC1.2 (22) and/or KC4 (14) anti-PADGEM mAbs.
Results
Construction ofLAM11PADGEMChimericcDNAs
To identify the regions of LAM-1 involved in cell adhesion,
and to determine the site and domain requirements ofcarbo-
hydrate binding, we constructed chimeric selectin cDNAs by
substituting homologous regions of PADGEM into LAM-1.
Novel restriction sites were introduced into the pLAM-1
eDNA (42) by PCR-based site-directed mutagenesis. Chi-
meric selectin cDNAs containing the 5' half of the lectin do-
main of LAM-1 (designated LIP), the entire lectin domain
352(UP), the lectin plus EGF domains (UP), or nearly the
entire extracellular portion (LAP) of LAM-1, with the re-
mainder of the cDNA as PADGEM, were constructed (Fig.
1) . In addition, a LAM-1 cDNA with only theEGFdomain
ofPADGEM substituted for that ofLAM-1 was constructed
(L2P3L). Chimeric selectin cDNAs with PADGEM at the 5'
endand LAM-1 at the 3' endwere also constructed, butwere
not expressed at detectable levels in COS cells. Because the
PADGEMandLAM-1 proteins sharean identicaldomain or-
ization (36),thesechimeric moleculesare likely to retain
erall topology oftheparent molecules . This approach
to analyzing functional domains has many advantages over
deletion analysis, whichmaychange theconformation ofthe
resulting molecules in unpredictable ways .
Binding ofPPME or Fucoidin Requires only
the Lectin DomainfromLAM-1
The chimeric selectins were subcloned into theAprm8COS
cell expression vector and analyzed forcarbohydrate binding
in transient transfection assays . Both PPME and fucoidin
bound to UP, which contains the entire lectin domain of
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Figure 1 . Diagramofchimeric se-
lectin cDNAs used in this study.
Restriction sites were introduced
separately into theLAM-1cDNA
as described in detail in Materials
and Methods (boldarrowsat top) .
The leader (L), lectin, EGF, SCR,
transmembrane (TM), cytoplas-
mic (C), and 3' untranslated
(3'UT) domains are indicated .
LAM-1 regions are in white, and
those derived fromPADGEM are
shaded . The double slash in the
PADGEMSCR region is to indi-
cate thatPADGEMhas nineSCR
repeats (unlikeLAM-1, which has
two), and all ofthem are included
in LIP, UP, andUP .
LAM-l, but notto PADGEM, or to LIP, which contains only
the 5' half of the lectin domain (Table I and Fig . 2) . At least
part of the binding site for these carbohydrates is therefore
located in, or requires, the 3' half of the lectin domain . In
addition, binding of both PPME and fucoidin to UP was
equivalent to or better than binding toLAM-1, or toUP or
L4P, which contain the lectin + EGF ofLAM-1 and the lec-
tin + EGF + short concensus repeat (SCR) domains of
LAM-1, respectively (see Fig . 1) . These data indicate that the
EGF and SCR domains ofPADGEM can replace those of
LAM-1 without affecting the binding ofPPME or fucoidin,
and therefore, that these domains ofLAM-1 are not required
for carbohydrate recognition and binding.
DomainMappingoftheBindingSitesofLAMI1,
LAMI-3, andLAMI-6 mAb
As described in detail elsewhere (34a), the LAMI-1, LAMI-3,
and LAMI-6 mAb each strongly inhibit the binding of lym-
phocytes to lymph node HEV in the frozen section assay, and
define three spatially distinct epitopes on the LAM-1 mole-
cule. To identify thedomain locations ofthe epitopes defined
COS cells transfected with LAM-1, PADGEM, or the chimeric selectin cDNAs wereanalyzed in transient transfection assays for staining with the indicated carbo-
hydrates or mAb, as described in Materials and Methods . PPME, fucoidin, LAMI-3, and LAM1-6 recognized the lectin domain of LAM-1, whereas LAMIA
expression was absent in chimeras lacking the LAW EGF domain .
LAM-1
ofLAM-1 Carbohydrate andmAb Binding Sites
Staining of COS cells transfected
PADGEM LIP UP
with cDNAs encoding
UP L4P L2P3L
PPME + + +++ ++ +++ ++I+
Fucoidin + + ++ ++ +++ +
LAMI-1 +++ ++ +++ -
LAMI-3 +++ +++ +++ ++++ ++
LAMI-6 +++ ++ ++ +++ +e of binding of carbohydrate or anti-LAM-1 monoclonal antibody to chimeric selectins. UP cDNA was expressed
OS cells, and binding ofmAb or carbohydrate was assessed as described in Materials and Methods . A-C, phase contrast; D-F, flu-
scence (FIT'C) . A and D, negative control; B and E, staining with LAMI-3 ; C and F, staining with PPME-FIT'C . Bar, 10 Am .
by these mAb, we analyzed the chimeric selectins as de-
scribed above. Similar to PPME and fucoidin, LAMI-3 and
LAMI-6 stained COS cells transfected with UP, UP, LAP,
andLAM-l, but notCOS cells transfected with UP orPAD-
GEM (Table I and Fig. 2), indicating that at least part of
the epitopes defined by these mAb are also located in, or
require, the 3' half of the lectin domain. Because LAMI-3
and LAMI-6 do not cross-block each others binding to
of Cell Biology, Volume 114, 1991
LAM-1 (34a), this demonstrates that LAMI-3 and LAMI-6
identify two distinct functional epitopes within the lectin do-
main . In contrast, binding ofLAMI-1 was not detected in
chimeras lacking the LAM-1 EGF domain (Table 1), indicat-
ing that the LAMl-1 epitope is within (or requires) the EGF
domain . In combination with the observation that both
PPME and fucoidin bind to chimeric selectins lacking the
LAM-1 EGF domain, these data suggest that the LAMI-1
354mAb, whichinhibits lymphocyte/HEV binding, recognizes a
domain ofLAM-1 whichis notrequired, i.e., canbe replaced
with that of PADGEM, for binding of PPME or fucoidin.
LAMI1, LAW-3, and LAMI-6 Have Distinct Effects
on Carbohydrate Binding
To directly relate the functional epitopes defined by these
mAb to the carbohydrate binding site, the effect of mAb
binding on thebinding ofPPME and fucoidin was assessed.
Peripheral blood lymphocytes were incubated with three- to
fivefold excess concentrations of each of these three mAbs,
followed by PPME-FITCor fucoidin-FITC, andanalyzed by
flow cytometry. Priorincubation of cells with LAMI-3 com-
pletely blocked the binding of both PPME-FITC and fu-
coidin-FITC (Fig. 3), suggesting that the LAMI-3 epitope
is at or in close proximity to the carbohydrate binding site.
In contrast, LAMI-6, which also strongly inhibits lympho-
cyte binding to HEV (34a)and also maps to thelectin domain
(Table I),had little or no effect on carbohydrate binding. Sur-
prisingly, the binding of LAMI-1 significantly enhanced the
binding ofboth PPME andfucoidin (Fig. 3), an effect which
varied 4-10-fold over several experiments. This enhanced
binding was also inhibited by the LAMI-3 mAb or EDTA
(datanot shown), indicating that this increased level of car-
bohydratebinding wasalso LAM-1 dependent. Thus, amAb
with antagonist activity in one functional assay of LAM-1
had agonist activity in a separate LAM-1 functional assay.
Discussion
The genetic mapping of functional domains of a number of
proteins that are members of gene families has been facili-
tatedby theconstruction andanalysis of chimeric molecules,
in which different regions of one family member are ex-
changedfor thecorrespondingregionsof adifferentmember
of the same family. Unlike deletion analysis, in which por-
tions of amolecule are simply removed, this approach pre-
serves the overall topology of the protein, thus preserving
some of thebiological properties oftheparent molecules. In
this report, we have used chimeric selectins to localize the
carbohydrate binding site within LAM4, and to locate the
epitopes identified by three mAb which inhibit lymphocyte
binding to HEV.
Our results directly demonstrate that bindingof PPME or
fucoidinby LAM-1 requires only thelectindomainofLAM-1,
and therefore suggest that the carbohydrate binding site is
contained within the lectin domain. The selective inhibition
of carbohydrate binding by LAMI-3 mAb (Fig. 3) suggests
that this antibody binds at or near the carbohydrate binding
site,asdefinedby PPME andfucoidin.Theseresults also dem-
onstrate that neither the EGF nor SCR domains of LAM-1
are necessary for carbohydrate binding, i.e., that the EGF
andSCRdomainsof PADGEM,whichdoes not bind PPME
or fucoidin in these assays (Table I), can subserve whatever
role, ifany, is played by thesedomainswith respectto carbo-
hydrate binding. These domains therefore probably do not
play an important role in determining the specificity of car-
bohydraterecognition . Theseresultsdo not, however, exclude
an essential structural role forthe EGF domain in ensuring
aproper conformation forthe lectin domain, as is suggested
by the observation that the EGF domains of MEL-14 and
Medium
EDTA
LAM I-3
LAM I-6
LAN I-1
PPME-FITC Fucoidtn-FITC
H
B
D
Figure 3 Effects of anti-LAM4 mAb on LAM-1/carbohydrate in-
teractions. Freshly isolated peripheral bloodlymphocytes were in-
cubated with saturating amounts of the indicated mAb, washed,
and stained with FITC-PPME or FITC-fucoidin, as described in
Materials andMethods. (A, C E, G, and I) Staining with PPME-
FITC; (B, D, F, H, andJ) staining with fucoidin-FITC; (A and B)
medium; (C andD) 10 mM EDTA; (E andF) LAMI-3; (Gand H)
LAMI-6; (I and J) LAMM. LAMI-3 blocks, LAMI-1 enhances,
and LAMI-6 has no effect, on the binding of both PPME and
fucoidin.
ELAM-1 were necessary to preserve epitopes identified by
the MEL-14 and H18/7 mAb, respectively (4, 45). That the
EGF domain of PADGEM can substitute for that of LAM-1
indicates that the structural features of the EGF domain,
which are apparently essential for lectin domain function,
have been well conserved among the selectins.
The LAMI-3 antibody resembles the MEL-14 antibody in
its inhibition of both PPME and lymphocyte/HEV binding,
and in the localization of its binding site to the lectin do-
main (4, 10, 48). The observation that PPME, fucoidin and
LAMI-3 each bind to L2P, which contains the entire lectin
domain of LAM-1, but not to LIP, which contains only the
amino-terminal 53 amino acid residues of LAM-1, suggests
that at least part of the carbohydrate/LAMI-3 binding site is
in the carboxy-terminal -67 amino acids of the lectin do-
main. Although these results would appear to differ from
those of Bowen et al., who used MEL-14/LAM-1 chimeras
to deduce that atleastpart oftheepitope forthe MEL-14 anti-
body is locatedin theamino-terminal 53 amino acids of the
lectin domain(4), thestrong homology betweentheselectins,
and the absolute conservation of the cysteine residues in the
lectin andEGF domains, suggests that both the MEL-14 and
LAMI-3 epitopes are actually conformationally determined
epitopes formed by residues present in both "halves" of theA Lectin domains
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Figure 4. Comparisonofamino acid sequences of the selectins. (A)
Lectin domains; (B) EGF domains. Dashes indicate identity at that
position with LAM-1. Residues that are identical between LAM-1
and MEL-14, but different from ELAM-1 and PADGEM, are indi-
cated by circles; closed circles indicate residues that are different
between ELAM-1 and PADGEM; open circles indicate residues
that are identicalbetween ELAM-1 and PADGEM. Open andclosed
triangles indicate conservative substitutions between MEL-14 and
LAM-1 at positions where ELAM-1 and PADGEM are different,
as above. Cysteine residues are indicated by an asterisk. Residues
found in all C-type lectins are indicated by a number sign. The ar-
row indicates the novel BamHI site used to create LIP; this is the
same site as the MroI site used to create the mhHR Mrol MEL-14/
LAM-1 chimera previously described by others (see reference 45).
lectin domain, and implies that the carbohydrate binding site
shares a similar structural requirement. Inthis regard, a num-
ber of residues can be identifiedin the lectin domain that are
shared by MEL-14 and LAM-1, but that are distinct for both
ELAM-I and PADGEM, suggesting that some of these resi-
dues may be involved in specific recognition ofcarbohydrate,
andthesepotential carbohydrate specificity determining resi-
dues are located largely unclustered throughoutthe lectin do-
main (Fig. 4 a) . A precedent for linearly noncontiguous resi-
dues of a protein comprising a carbohydrate binding site is
the well characterized hemagglutinin of influenza virus (re-
viewed in reference 5) . Identification of the precise residues
which are responsible for carbohydrate recognitionand bind-
ing by these and other C-type animal lectins awaits further
experimentation.
The region defined by the LAMI-6 mAb, which, like the
LAMI-3 mAb, inhibits lymphocyte adhesion to HEV, is also
within the lectin domain (Table I), but at a site spatially dis-
tinct from the LAMI-3/carbohydrate binding site. This sug-
gests that two distinct regions within the lectin domain of
LAM-1 are involved in lymphocyte adhesion to HEV. Al-
though a number of structurally unrelated polysaccharides,
including PPME, fucoidin, and sulfatide,can selectively and
specifically inhibit lymphocyte adhesion to LN HEV (15),
it seems unlikely that the lectin domain recognizes two sepa-
rate,distinct, and unrelated carbohydrates. Rather, it is more
likely that each ofthese different reagents resembles the phys-
iologic carbohydrate ligand or a component thereof, there-
by allowing recognition by LAM-1/MEL-14. Although the
LAMI-6 mAb does not inhibit the binding of PPME or fu-
coidin (Fig. 3), it remains possible that inhibition of HEV
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binding by LAMI-6 may be due to steric hindrance of lectin
domain activity (i.e., recognition of carbohydrate) that is not
detectable by analysis of PPME or fucoidin binding. In this
regard, itshould be explicitlyemphasizedthatthe soluble car-
bohydratesused in these and other studies areunlikely to per-
fectly model the physiologic carbohydrate ligand. It is there-
fore possible that the effects ofmAb on the binding of PPME
or fucoidin do not accurately predict the effect of these mAb
on the recognition of the natural carbohydrate ligand by the
lectin domain in the course of cell adhesion in vivo.
The LAMI-1 mAb also inhibits lymphocyte/HEV interac-
tions, and the epitope defined by LAM1-1 is within, or re-
quires, the EGF domain (Table I). These properties are iden-
tical to what has been described for the Ly-22 mAb, which
also recognizes the MEL-14 antigen (32). The observation
that this antibody enhances the binding of both PPME and
fucoidin (Fig. 3) makes it less likely that inhibition of HEV
binding by LAMI-1 is due to inhibition ofcarbohydrate bind-
ing. However, as indicated above, these data do not exclude
the possibility that LAMW inhibits recognition of the natu-
ral carbohydrate ligand. It also seems unlikely that inhibition
of HEV binding by LAMW is due to general allosteric
effects, because the binding of the Leu-8 and LAMI-3 mAb,
which identify distinct epitopes in the lectin domain (refer-
ence 45 and Table I), is unaffected by LAMI-1 (34a and
data not shown) . Moreover, with respect to carbohydrate
binding, the EGF domain of LAM-1 can be replaced with
that of PADGEM (Table I). In addition, the degree ofamino
acid identity between the EGF domains of the selectins is
equal to that found in the lectin domains (63-67%) (Fig. 3
b), suggesting an equally important role in the function of
these molecules. Numerous examples of EGF-like domains
mediating specific interactions between proteins exist (re-
viewed in reference 8) . These observations are consistent
with the existence ofa second binding site, which is essential
for lymphocyte binding to HEV, within the EGF domain.
A binding mechanism which involves interaction at two
sitesmight be advantageous for several reasons. Suchamech-
anism might plausibly be expected to confer a high degree
of specificity on the adhesive event. This consideration ap-
pears particularly relevant, given recent evidence indicating
thatthe carbohydrate ligands ofthe selectinsareclosely struc-
turally related: each contains sialic acid, and the ELAM-1
and PADGEM carbohydrate ligands include the sLex and
Lex structures, respectively (7, 23, 26, 27, 28, 44-46) . Bind-
ing via two sites, especially ifcooperative, would also be ex-
pected to generate an interaction of higher avidity, which
would be important given the apparently low affinity of
LAM-1 for PPME or fucoidin, of PADGEM for CD15/
LNFIII/Lex, and of ELAM-1 for sLex (23, 26, 45) . In addi-
tion, a requirement for dual recognition of separate ligand
components would allow the use of a limited number of car-
bohydratesand EGF-like domains to generate a larger num-
ber of specificities, thus obviating the need to evolve a large
number of lectin domains. This last consideration may par-
tially account for the unique mosaic ofprotein motifs charac-
teristic of the selectins.
The unanticipated enhancement of carbohydrate binding
by prior binding ofLAMM mAb raises interesting questions
regarding the nature of receptor/ligand interactions. We have
previously shown that activation of T cells by cross-linking
CD3/TCR or CD2, or neutrophils by GM-CSF or TNF-«,
356leads to a rapid and transient upregulation ofPPME binding
activity by a mechanism which involves the upregulation of
affinity of LAM-1 for ligand (34) . This enhanced binding
of PPME is indistinguishable from that produced by binding
of LAM1-1 mAb. Taken together, these observations suggest
that the EGF domain may be involved in the regulation of
receptor function, including the increase inaffinity ofLAM-1
for carbohydrate associated with cellular activation.
The role ofthe SCR domains in the function of LAM-1 and
the other selectins remains undefined. Our findings suggest
that this region is not directly involved in cell adhesion, and
therefore suggest that the SCR domains subserve primarily
a structural requirement, perhaps by extending the adhesive
domains sufficiently far from the glycocalyx to ensure ef-
ficientcell adhesion. This is consistentwiththe variablenum-
ber ofSCR domains found in the different selectins, and with
the lowerdegree of conservation exhibited by SCR domains
compared with the other regions of these adhesion proteins.
In the case ofLAM-1 and MEL-14, this region may also be
involved in the shedding of the molecule associated with cel-
lular activation (17, 20, 33, 43).
In summary, we have demonstrated that antibodies to
LAM-1 that inhibit lymphocyte adhesion to HEV have con-
trasting effects on the ability of LAM-1 to recognize PPME
and fucoidin, soluble carbohydrates which bind to LAM-1
and inhibit adhesion to LN HEV. In addition, we have shown
that these antibodies identify distinct regions in different do-
mains of the molecule. Our findings therefore reinforce data
indirectly suggesting a role for the EGF domain in cell adhe-
sion (32). Whether the EGF domain plays a role in support-
ing the appropriate conformation of the lectin domain, as
suggested (4), participates directly in cell adhesion, or plays
some other, unexpected role, awaits further investigation.
Analysis of the ability of the chimeric selectins described in
this paper to confer HEV binding, currently in progress, may
provide a more definitive answer to this question .
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